Baseline characteristics | All patients | MED | CABG | P value |
Number of subjects | 875 | 466 | 409 | 0.70 |
Age (years) Mean±SD | 60.0±9.0 | 60.0±9.2 | 60.0±8.7 | 0.66 |
Male, n (%) | 774 (88.5) | 412 (88.4) | 362 (88.5) | 0.97 |
Region of enrolment, n (%) | 0.80 | |||
Poland | 273 (31.2) | 145 (31.1) | 128 (31.3) | |
USA/Canada | 151 (17.3) | 83 (17.8) | 68 (16.6) | |
West Europe | 73 (8.3) | 42 (9.0) | 31 (7.6) | |
Other | 378 (43.2) | 196 (42.1) | 182 (44.5) | |
Ethnic minority, n (%) | 270 (30.9) | 138 (29.6) | 132 (32.3) | 0.40 |
Hyperlipidaemia, n (%) | 526 (60.2) | 285 (61.3) | 241 (58.9) | 0.48 |
Hypertension, n (%) | 527 (60.2) | 285 (61.2) | 242 (59.2) | 0.55 |
Diabetes, n (%) | 344 (39.3) | 189 (40.6) | 155 (37.9) | 0.42 |
Peripheral vascular disease, n (%) | 117 (13.4) | 70 (15.0) | 47 (11.5) | 0.13 |
Chronic renal insufficiency, n (%) | 44 (5.0) | 25 (5.4) | 19 (4.7) | 0.63 |
Atrial fibrillation/flutter, n (%) | 105 (12.0) | 59 (12.7) | 46 (11.2) | 0.52 |
Current smoker, n (%) | 169 (19.3) | 91 (19.6) | 78 (19.1) | 0.85 |
Depression, n (%) | 42 (4.8) | 20 (4.3) | 22 (5.4) | 0.45 |
Current angina class ≥II, n (%) | 412 (72.7) | 219 (73.7) | 193 (71.5) | 0.55 |
Current NYHA ≥III, n (%) | 283 (32.3) | 155 (33.3) | 128 (31.3) | 0.54 |
BMI (kg/m2) | 27.4±4.6 | 27.4±4.7 | 27.4±4.5 | 0.85 |
LVEF (%) | 28.3±8.9 | 28.6±9.1 | 27.9±8.7 | 0.41 |
LV end systolic volume index | 85.7±36.3 | 87.1±37.5 | 84.1±34.9 | 0.30 |
Moderate-severe mitral regurgitation, n (%) | 157 (18.0) | 92 (19.8) | 65 (15.9) | 0.14 |
Three vessel/stenosis ≥75%, n (%) | 304 (34.7) | 156 (33.5) | 148 (36.2) | 0.40 |
Physical activity score* | 71 (50.0, 88.0) | 71 (50.0, 88.0) | 71 (50.0, 88.0) | 0.45 |
KCCQ score | 64 (47.0, 80.0) | 63.5 (47.0, 82.0) | 64 (47.0, 79.0) | 0.65 |
*Median (25th and 75th).
6 MW, 6 min walk; BMI, body mass index; CABG, coronary artery bypass grafting; KCCQ, Kansas City Cardiomyopathy Questionnaire; LV, left ventricular; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; NYHA, New York Heart Association; STICH, Surgical Treatment for Ischemic Heart Failure trial.